Sage Therapeutics (SAGE, Financial) fell on disappointing data from a Phase 3 clinical trial of its drug SAGE-217 in major depression (MDD). The promise of SAGE-217 in the MDD market was a key element of our investment rationale.
Sage Therapeutics reported disappointing data from a Phase 3 clinical trial of its drug SAGE-217 in major depression (MDD). The drug’s statistically significant efficacy and strong safety profile in post-partum depression (PPD) were thought to bode well for its commercial applications in MDD. MDD represents a much larger unmet medical need than PPD, and the promise of SAGE-217 in the MDD market was a key element of our investment rationale.
From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund fourth-quarter 2019 commentary.
